Cargando…

An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains

In this study, the cell free modified tryptone soya broth (pH 7.4 ± 0.2) of Bacillus subtilis URID 12.1 showed significant antimicrobial activity against multidrug-resistant strains of Staphylococcus aureus, S. epidermidis, Streptococcus pyogenes and Enterococcus faecalis. The partially purified ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalasani, Ajay G., Dhanarajan, Gunaseelan, Nema, Sushma, Sen, Ramkrishna, Roy, Utpal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678185/
https://www.ncbi.nlm.nih.gov/pubmed/26696963
http://dx.doi.org/10.3389/fmicb.2015.01335
_version_ 1782405409798094848
author Chalasani, Ajay G.
Dhanarajan, Gunaseelan
Nema, Sushma
Sen, Ramkrishna
Roy, Utpal
author_facet Chalasani, Ajay G.
Dhanarajan, Gunaseelan
Nema, Sushma
Sen, Ramkrishna
Roy, Utpal
author_sort Chalasani, Ajay G.
collection PubMed
description In this study, the cell free modified tryptone soya broth (pH 7.4 ± 0.2) of Bacillus subtilis URID 12.1 showed significant antimicrobial activity against multidrug-resistant strains of Staphylococcus aureus, S. epidermidis, Streptococcus pyogenes and Enterococcus faecalis. The partially purified antimicrobial molecule was found to be resistant to extremes of pH and temperatures and also to higher concentrations of trypsin and proteinase K. The antimicrobial molecule was purified by a three-step method that included reversed-phase high performance liquid chromatography (RP-HPLC). The minimum inhibitory concentration (MIC) values were determined for 14 species of bacteria using a microbroth dilution technique. The HPLC-purified fraction showed the MICs ranging from 0.5 to 16 μg/ml for methicillin and vancomycin-resistant Staphylococcus aureus (MVRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) strains. The molecular mass of the antimicrobial compound was determined to be 842.37 Da. The same antimicrobial fraction showed negligible haemolytic activity against human red blood cells even at a concentration as high as 100 μg/ml. Because of its significant antimicrobial activity at low MIC values coupled with its non-haemolytic property, it may prove to be a novel antimicrobial lead molecule.
format Online
Article
Text
id pubmed-4678185
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-46781852015-12-22 An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains Chalasani, Ajay G. Dhanarajan, Gunaseelan Nema, Sushma Sen, Ramkrishna Roy, Utpal Front Microbiol Microbiology In this study, the cell free modified tryptone soya broth (pH 7.4 ± 0.2) of Bacillus subtilis URID 12.1 showed significant antimicrobial activity against multidrug-resistant strains of Staphylococcus aureus, S. epidermidis, Streptococcus pyogenes and Enterococcus faecalis. The partially purified antimicrobial molecule was found to be resistant to extremes of pH and temperatures and also to higher concentrations of trypsin and proteinase K. The antimicrobial molecule was purified by a three-step method that included reversed-phase high performance liquid chromatography (RP-HPLC). The minimum inhibitory concentration (MIC) values were determined for 14 species of bacteria using a microbroth dilution technique. The HPLC-purified fraction showed the MICs ranging from 0.5 to 16 μg/ml for methicillin and vancomycin-resistant Staphylococcus aureus (MVRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) strains. The molecular mass of the antimicrobial compound was determined to be 842.37 Da. The same antimicrobial fraction showed negligible haemolytic activity against human red blood cells even at a concentration as high as 100 μg/ml. Because of its significant antimicrobial activity at low MIC values coupled with its non-haemolytic property, it may prove to be a novel antimicrobial lead molecule. Frontiers Media S.A. 2015-12-15 /pmc/articles/PMC4678185/ /pubmed/26696963 http://dx.doi.org/10.3389/fmicb.2015.01335 Text en Copyright © 2015 Chalasani, Dhanarajan, Nema, Sen and Roy. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Chalasani, Ajay G.
Dhanarajan, Gunaseelan
Nema, Sushma
Sen, Ramkrishna
Roy, Utpal
An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains
title An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains
title_full An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains
title_fullStr An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains
title_full_unstemmed An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains
title_short An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains
title_sort antimicrobial metabolite from bacillus sp.: significant activity against pathogenic bacteria including multidrug-resistant clinical strains
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678185/
https://www.ncbi.nlm.nih.gov/pubmed/26696963
http://dx.doi.org/10.3389/fmicb.2015.01335
work_keys_str_mv AT chalasaniajayg anantimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains
AT dhanarajangunaseelan anantimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains
AT nemasushma anantimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains
AT senramkrishna anantimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains
AT royutpal anantimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains
AT chalasaniajayg antimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains
AT dhanarajangunaseelan antimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains
AT nemasushma antimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains
AT senramkrishna antimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains
AT royutpal antimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains